Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tetracaine Compared to Placebo for Reducing Pain With Palivizumab - A Pilot Study

This study has been completed.
Information provided by:
Fraser Health Identifier:
First received: June 6, 2007
Last updated: May 27, 2008
Last verified: May 2008

This is a small study known as a pilot study. This pilot study is being done to see if a difference in pain from intramuscular palivizumab injection can be detected if tetracaine a topical numbing gel is used compared to no medication (placebo). If a difference is found in this pilot study, then a larger study may be done to confirm that there is a difference in pain experience.

Condition Intervention Phase
Pain From Intramuscular Palivizumab Injection
Drug: tetracaine 4% gel
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Supportive Care
Official Title: Tetracaine (Ametop®) Compared to Placebo for Reducing Pain Associated With Intramuscular Injection of Palivizumab (Synagis®) - A Pilot Study

Resource links provided by NLM:

Further study details as provided by Fraser Health:

Primary Outcome Measures:
  • To determine if a difference in pain scale ratings is detectable following intramuscular palivizumab injection that was pre-treated with placebo or tetracaine. [ Time Frame: 2 visits, 1 month apart ]

Secondary Outcome Measures:
  • Adverse effects associated with tetracaine. [ Time Frame: 2 visits, 1 month apart ]

Enrollment: 7
Study Start Date: November 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   1 Month to 2 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Infants between 1 month and 2 years of age receiving palivizumab at Surrey Memorial Hospital for 2 consecutive intramuscular injections during the 2007/8 season
  • Parents need to complete informed consent.

Exclusion Criteria:

  • Allergy/sensitivity to tetracaine, or ester type anaesthetics.
  • Infants who present with fever or illness that prevent administration of palivizumab.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00484393

Canada, British Columbia
Surrey Memorial Hospital
Surrey, British Columbia, Canada, V3V1Z2
Sponsors and Collaborators
Fraser Health
Principal Investigator: Brandi D Newby, BScPharm Surrey Memorial Hospital
  More Information


Responsible Party: BNewby, Pharmacist, Fraser Health Identifier: NCT00484393     History of Changes
Other Study ID Numbers: 2007-041
Study First Received: June 6, 2007
Last Updated: May 27, 2008
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:
Anesthetics, Local
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on March 03, 2015